Another IL-6 Blocker Succeeds in Rheumatoid Arthritis

(MedPage Today) -- An investigational biologic that targets interleukin (IL)-6, olokizumab, was effective for patients with moderately to severely active rheumatoid arthritis (RA) that had been inadequately controlled with methotrexate in a phase...